#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Effects	_
1-2	8-10	of	_
1-3	11-19	familial	_
1-4	20-24	risk	_
1-5	25-28	and	_
1-6	29-38	stimulant	_
1-7	39-43	drug	_
1-8	44-47	use	_
1-9	48-50	on	_
1-10	51-54	the	_
1-11	55-67	anticipation	_
1-12	68-70	of	_
1-13	71-79	monetary	_
1-14	80-86	reward	_
1-15	87-88	:	_
1-16	89-91	an	_
1-17	92-96	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	97-102	study	_
1-19	103-106	The	_
1-20	107-118	association	_
1-21	119-126	between	_
1-22	127-136	stimulant	_
1-23	137-141	drug	_
1-24	142-145	use	_
1-25	146-149	and	_
1-26	150-158	aberrant	_
1-27	159-165	reward	_
1-28	166-176	processing	_
1-29	177-179	is	_
1-30	180-195	well-documented	_
1-31	196-198	in	_
1-32	199-202	the	_
1-33	203-213	literature	_
1-34	214-215	,	_
1-35	216-219	but	_
1-36	220-223	the	_
1-37	224-230	nature	_
1-38	231-233	of	_
1-39	234-239	these	_
1-40	240-253	abnormalities	_
1-41	254-261	remains	_
1-42	262-269	elusive	_
1-43	270-271	.	_

2-1	272-275	The	_
2-2	276-283	present	_
2-3	284-289	study	_
2-4	290-294	aims	_
2-5	295-297	to	_
2-6	298-309	disentangle	_
2-7	310-313	the	_
2-8	314-322	separate	_
2-9	323-326	and	_
2-10	327-338	interacting	_
2-11	339-346	effects	_
2-12	347-349	of	_
2-13	350-359	stimulant	_
2-14	360-364	drug	_
2-15	365-368	use	_
2-16	369-372	and	_
2-17	373-385	pre-existing	_
2-18	386-394	familial	_
2-19	395-399	risk	_
2-20	400-402	on	_
2-21	403-411	abnormal	_
2-22	412-418	reward	_
2-23	419-429	processing	_
2-24	430-440	associated	_
2-25	441-445	with	_
2-26	446-455	stimulant	_
2-27	456-460	drug	_
2-28	461-470	addiction	_
2-29	471-472	.	_

3-1	473-475	We	_
3-2	476-480	used	_
3-3	481-484	the	_
3-4	485-493	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-5	494-503	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-6	504-509	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-7	510-514	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-8	515-516	,	_
3-9	517-518	a	_
3-10	519-533	well-validated	_
3-11	534-541	measure	_
3-12	542-544	of	_
3-13	545-551	reward	_
3-14	552-562	processing	_
3-15	563-564	,	_
3-16	565-571	during	_
3-17	572-576	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-18	577-585	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
3-19	586-588	in	_
3-20	589-593	four	_
3-21	594-602	distinct	_
3-22	603-609	groups	_
3-23	610-611	:	_
3-24	612-623	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-25	624-628	with	_
3-26	629-637	familial	_
3-27	638-642	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-28	643-646	who	_
3-29	647-651	were	_
3-30	652-658	either	_
3-31	659-668	stimulant	_
3-32	669-683	drug-dependent	_
3-33	684-685	(	_
3-34	686-687	N	_
3-35	688-689	=	_
3-36	690-692	41	_
3-37	693-694	)	_
3-38	695-697	or	_
3-39	698-701	had	_
3-40	702-707	never	_
3-41	708-712	used	_
3-42	713-722	stimulant	_
3-43	723-728	drugs	_
3-44	729-730	(	_
3-45	731-732	N	_
3-46	733-734	=	_
3-47	735-737	46	_
3-48	738-739	)	_
3-49	740-741	;	_
3-50	742-745	and	_
3-51	746-757	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-52	758-765	without	_
3-53	766-774	familial	_
3-54	775-779	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-55	780-783	who	_
3-56	784-788	were	_
3-57	789-795	either	_
3-58	796-801	using	_
3-59	802-811	stimulant	_
3-60	812-817	drugs	_
3-61	818-819	(	_
3-62	820-821	N	_
3-63	822-823	=	_
3-64	824-826	25	_
3-65	827-828	)	_
3-66	829-831	or	_
3-67	832-835	not	_
3-68	836-837	(	_
3-69	838-839	N	_
3-70	840-841	=	_
3-71	842-844	48	_
3-72	845-846	)	_
3-73	847-848	.	_

4-1	849-851	We	_
4-2	852-857	first	_
4-3	858-866	examined	_
4-4	867-879	task-related	_
4-5	880-891	whole-brain	_
4-6	892-902	activation	_
4-7	903-911	followed	_
4-8	912-914	by	_
4-9	915-916	a	_
4-10	917-936	psychophysiological	_
4-11	937-948	interaction	_
4-12	949-957	analysis	_
4-13	958-960	to	_
4-14	961-968	further	_
4-15	969-976	explore	_
4-16	977-982	brain	_
4-17	983-993	functional	_
4-18	994-1006	connectivity	_
4-19	1007-1008	.	_

5-1	1009-1012	For	_
5-2	1013-1021	analyses	_
5-3	1022-1023	,	_
5-4	1024-1026	we	_
5-5	1027-1031	used	_
5-6	1032-1033	a	_
5-7	1034-1044	univariate	_
5-8	1045-1050	model	_
5-9	1051-1055	with	_
5-10	1056-1059	two	_
5-11	1060-1065	fixed	_
5-12	1066-1073	factors	_
5-13	1074-1075	(	_
5-14	1076-1084	familial	_
5-15	1085-1089	risk	_
5-16	1090-1093	and	_
5-17	1094-1103	stimulant	_
5-18	1104-1108	drug	_
5-19	1109-1112	use	_
5-20	1113-1114	)	_
5-21	1115-1116	.	_

6-1	1117-1120	Our	_
6-2	1121-1128	results	_
6-3	1129-1135	showed	_
6-4	1136-1145	increased	_
6-5	1146-1158	task-related	_
6-6	1159-1169	activation	_
6-7	1170-1172	in	_
6-8	1173-1176	the	_
6-9	1177-1184	putamen	_
6-10	1185-1188	and	_
6-11	1189-1194	motor	_
6-12	1195-1201	cortex	_
6-13	1202-1204	of	_
6-14	1205-1220	stimulant-using	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
6-15	1221-1233	participants	_
6-16	1234-1235	.	_

7-1	1236-1238	We	_
7-2	1239-1243	also	_
7-3	1244-1249	found	_
7-4	1250-1257	altered	_
7-5	1258-1270	task-related	_
7-6	1271-1281	functional	_
7-7	1282-1294	connectivity	_
7-8	1295-1302	between	_
7-9	1303-1306	the	_
7-10	1307-1314	putamen	_
7-11	1315-1318	and	_
7-12	1319-1326	frontal	_
7-13	1327-1334	regions	_
7-14	1335-1337	in	_
7-15	1338-1350	participants	_
7-16	1351-1355	with	_
7-17	1356-1357	a	_
7-18	1358-1366	familial	_
7-19	1367-1371	risk	_
7-20	1372-1373	(	_
7-21	1374-1386	irrespective	_
7-22	1387-1389	of	_
7-23	1390-1397	whether	_
7-24	1398-1402	they	_
7-25	1403-1407	were	_
7-26	1408-1413	using	_
7-27	1414-1423	stimulant	_
7-28	1424-1429	drugs	_
7-29	1430-1432	or	_
7-30	1433-1436	not	_
7-31	1437-1438	)	_
7-32	1439-1440	.	_

8-1	1441-1453	Additionally	_
8-2	1454-1455	,	_
8-3	1456-1458	we	_
8-4	1459-1469	identified	_
8-5	1470-1472	an	_
8-6	1473-1484	interaction	_
8-7	1485-1492	between	_
8-8	1493-1502	stimulant	_
8-9	1503-1507	drug	_
8-10	1508-1511	use	_
8-11	1512-1515	and	_
8-12	1516-1524	familial	_
8-13	1525-1529	risk	_
8-14	1530-1532	in	_
8-15	1533-1545	task-related	_
8-16	1546-1556	functional	_
8-17	1557-1569	connectivity	_
8-18	1570-1577	between	_
8-19	1578-1581	the	_
8-20	1582-1589	putamen	_
8-21	1590-1593	and	_
8-22	1594-1607	motor-related	_
8-23	1608-1616	cortical	_
8-24	1617-1624	regions	_
8-25	1625-1627	in	_
8-26	1628-1639	potentially	_
8-27	1640-1647	at-risk	_
8-28	1648-1659	individuals	_
8-29	1660-1661	.	_

9-1	1662-1665	Our	_
9-2	1666-1674	findings	_
9-3	1675-1682	suggest	_
9-4	1683-1687	that	_
9-5	1688-1696	abnormal	_
9-6	1697-1709	task-related	_
9-7	1710-1720	activation	_
9-8	1721-1723	in	_
9-9	1724-1729	motor	_
9-10	1730-1735	brain	_
9-11	1736-1743	systems	_
9-12	1744-1746	is	_
9-13	1747-1757	associated	_
9-14	1758-1762	with	_
9-15	1763-1770	regular	_
9-16	1771-1780	stimulant	_
9-17	1781-1785	drug	_
9-18	1786-1789	use	_
9-19	1790-1791	,	_
9-20	1792-1799	whereas	_
9-21	1800-1808	abnormal	_
9-22	1809-1821	task-related	_
9-23	1822-1832	functional	_
9-24	1833-1845	connectivity	_
9-25	1846-1848	in	_
9-26	1849-1863	frontostriatal	_
9-27	1864-1869	brain	_
9-28	1870-1877	systems	_
9-29	1878-1879	,	_
9-30	1880-1882	in	_
9-31	1883-1894	individuals	_
9-32	1895-1899	with	_
9-33	1900-1908	familial	_
9-34	1909-1913	risk	_
9-35	1914-1915	,	_
9-36	1916-1919	may	_
9-37	1920-1928	indicate	_
9-38	1929-1941	pre-existing	_
9-39	1942-1948	neural	_
9-40	1949-1962	vulnerability	_
9-41	1963-1966	for	_
9-42	1967-1977	developing	_
9-43	1978-1987	addiction	_
9-44	1988-1989	.	_

10-1	1990-1999	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	2000-2003	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	2004-2011	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	2012-2017	Study	_
10-5	2018-2024	sample	_
10-6	2025-2026	A	_
10-7	2027-2032	total	_
10-8	2033-2035	of	_
10-9	2036-2039	165	_
10-10	2040-2052	participants	_
10-11	2053-2057	were	_
10-12	2058-2067	recruited	_
10-13	2068-2071	for	_
10-14	2072-2076	this	_
10-15	2077-2082	study	_
10-16	2083-2087	from	_
10-17	2088-2093	local	_
10-18	2094-2103	treatment	_
10-19	2104-2111	centers	_
10-20	2112-2113	,	_
10-21	2114-2116	by	_
10-22	2117-2122	media	_
10-23	2123-2137	advertisements	_
10-24	2138-2139	,	_
10-25	2140-2142	or	_
10-26	2143-2145	by	_
10-27	2146-2159	word-of-mouth	_
10-28	2160-2166	within	_
10-29	2167-2170	the	_
10-30	2171-2180	community	_
10-31	2181-2182	.	_

11-1	2183-2186	All	_
11-2	2187-2199	participants	_
11-3	2200-2204	were	_
11-4	2205-2212	between	_
11-5	2213-2216	the	_
11-6	2217-2220	age	_
11-7	2221-2223	of	_
11-8	2224-2229	18â€“55	_
11-9	2230-2235	years	_
11-10	2236-2239	and	_
11-11	2240-2246	fluent	_
11-12	2247-2249	in	_
11-13	2250-2257	written	_
11-14	2258-2261	and	_
11-15	2262-2268	spoken	_
11-16	2269-2276	English	_
11-17	2277-2278	.	_

12-1	2279-2291	Participants	_
12-2	2292-2296	also	_
12-3	2297-2306	underwent	_
12-4	2307-2322	semi-structured	_
12-5	2323-2333	interviews	_
12-6	2334-2336	to	_
12-7	2337-2346	ascertain	_
12-8	2347-2355	personal	_
12-9	2356-2359	and	_
12-10	2360-2366	family	_
12-11	2367-2374	history	_
12-12	2375-2377	of	_
12-13	2378-2390	drug/alcohol	_
12-14	2391-2400	addiction	_
12-15	2401-2402	,	_
12-16	2403-2411	physical	_
12-17	2412-2418	health	_
12-18	2419-2420	(	_
12-19	2421-2430	including	_
12-20	2431-2436	signs	_
12-21	2437-2439	of	_
12-22	2440-2445	acute	_
12-23	2446-2458	intoxication	_
12-24	2459-2462	and	_
12-25	2463-2473	withdrawal	_
12-26	2474-2475	)	_
12-27	2476-2477	,	_
12-28	2478-2481	and	_
12-29	2482-2488	mental	_
12-30	2489-2495	health	_
12-31	2496-2498	as	_
12-32	2499-2507	assessed	_
12-33	2508-2512	with	_
12-34	2513-2516	the	_
12-35	2517-2527	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-36	2528-2536	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-37	2537-2546	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-38	2547-2550	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-39	2551-2560	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-40	2561-2565	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-41	2566-2567	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-42	2568-2577	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
12-43	2578-2579	.	_

13-1	2580-2592	Participants	_
13-2	2593-2597	were	_
13-3	2598-2603	split	_
13-4	2604-2608	into	_
13-5	2609-2613	four	_
13-6	2614-2620	groups	_
13-7	2621-2626	based	_
13-8	2627-2629	on	_
13-9	2630-2635	their	_
13-10	2636-2646	individual	_
13-11	2647-2655	familial	_
13-12	2656-2660	risk	_
13-13	2661-2662	(	_
13-14	2663-2664	F	_
13-15	2665-2666	)	_
13-16	2667-2670	and	_
13-17	2671-2680	stimulant	_
13-18	2681-2693	drug-related	_
13-19	2694-2698	risk	_
13-20	2699-2700	(	_
13-21	2701-2702	S	_
13-22	2703-2704	)	_
13-23	2705-2706	.	_

14-1	2707-2726	Stimulant-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-2	2727-2738	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
14-3	2739-2740	(	_
14-4	2741-2745	F+S+	_
14-5	2746-2747	)	_
14-6	2748-2751	and	_
14-7	2752-2757	their	_
14-8	2758-2768	unaffected	_
14-9	2769-2777	siblings	_
14-10	2778-2779	(	_
14-11	2780-2784	F+Sâˆ’	_
14-12	2785-2786	)	_
14-13	2787-2795	composed	_
14-14	2796-2799	the	_
14-15	2800-2806	groups	_
14-16	2807-2811	with	_
14-17	2812-2820	familial	_
14-18	2821-2825	risk	_
14-19	2826-2827	.	_

15-1	2828-2841	Non-dependent	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
15-2	2842-2851	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
15-3	2852-2856	drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-4	2857-2862	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-5	2863-2870	without	_
15-6	2871-2872	a	_
15-7	2873-2879	family	_
15-8	2880-2887	history	_
15-9	2888-2890	of	_
15-10	2891-2900	addiction	_
15-11	2901-2902	(	_
15-12	2903-2907	Fâˆ’S+	_
15-13	2908-2909	)	_
15-14	2910-2913	and	_
15-15	2914-2925	individuals	_
15-16	2926-2933	without	_
15-17	2934-2940	either	_
15-18	2941-2947	family	_
15-19	2948-2950	or	_
15-20	2951-2959	personal	_
15-21	2960-2967	history	_
15-22	2968-2970	of	_
15-23	2971-2975	drug	_
15-24	2976-2985	addiction	_
15-25	2986-2987	(	_
15-26	2988-2992	Fâˆ’Sâˆ’	_
15-27	2993-2994	)	_
15-28	2995-3003	composed	_
15-29	3004-3007	the	_
15-30	3008-3015	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
15-31	3016-3022	groups	_
15-32	3023-3030	without	_
15-33	3031-3039	familial	_
15-34	3040-3044	risk	_
15-35	3045-3046	(	_
15-36	3047-3050	see	_
15-37	3051-3056	Table	_
15-38	3057-3058	1	_
15-39	3059-3060	)	_
15-40	3061-3062	.	_

16-1	3063-3066	All	_
16-2	3067-3071	F+S+	_
16-3	3072-3084	participants	_
16-4	3085-3089	were	_
16-5	3090-3098	required	_
16-6	3099-3101	to	_
16-7	3102-3109	satisfy	_
16-8	3110-3113	the	_
16-9	3114-3123	DSM-IV-TR	_
16-10	3124-3132	criteria	_
16-11	3133-3136	for	_
16-12	3137-3146	stimulant	_
16-13	3147-3151	drug	_
16-14	3152-3162	dependence	_
16-15	3163-3164	(	_
16-16	3165-3172	cocaine	_
16-17	3173-3174	:	_
16-18	3175-3179	92.7	_
16-19	3180-3181	%	_
16-20	3182-3183	;	_
16-21	3184-3196	amphetamines	_
16-22	3197-3198	:	_
16-23	3199-3202	7.3	_
16-24	3203-3204	%	_
16-25	3205-3206	)	_
16-26	3207-3210	and	_
16-27	3211-3216	share	_
16-28	3217-3221	both	_
16-29	3222-3232	biological	_
16-30	3233-3240	parents	_
16-31	3241-3245	with	_
16-32	3246-3248	an	_
16-33	3249-3253	F+Sâˆ’	_
16-34	3254-3261	sibling	_
16-35	3262-3265	who	_
16-36	3266-3269	was	_
16-37	3270-3274	also	_
16-38	3275-3279	able	_
16-39	3280-3282	to	_
16-40	3283-3294	participate	_
16-41	3295-3297	in	_
16-42	3298-3301	the	_
16-43	3302-3307	study	_
16-44	3308-3309	.	_

17-1	3310-3322	Additionally	_
17-2	3323-3324	,	_
17-3	3325-3329	Fâˆ’S+	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
17-4	3330-3337	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
17-5	3338-3350	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
17-6	3351-3355	were	_
17-7	3356-3364	required	_
17-8	3365-3367	to	_
17-9	3368-3372	have	_
17-10	3373-3380	engaged	_
17-11	3381-3383	in	_
17-12	3384-3391	regular	_
17-13	3392-3401	stimulant	_
17-14	3402-3406	drug	_
17-15	3407-3410	use	_
17-16	3411-3414	for	_
17-17	3415-3417	at	_
17-18	3418-3423	least	_
17-19	3424-3427	two	_
17-20	3428-3433	years	_
17-21	3434-3437	but	_
17-22	3438-3441	had	_
17-23	3442-3447	never	_
17-24	3448-3457	developed	_
17-25	3458-3467	addiction	_
17-26	3468-3470	to	_
17-27	3471-3476	drugs	_
17-28	3477-3479	or	_
17-29	3480-3487	alcohol	_
17-30	3488-3491	and	_
17-31	3492-3495	had	_
17-32	3496-3501	never	_
17-33	3502-3506	been	_
17-34	3507-3517	prescribed	_
17-35	3518-3527	stimulant	_
17-36	3528-3533	drugs	_
17-37	3534-3537	for	_
17-38	3538-3545	medical	_
17-39	3546-3553	reasons	_
17-40	3554-3555	.	_

18-1	3556-3558	We	_
18-2	3559-3572	intentionally	_
18-3	3573-3582	recruited	_
18-4	3583-3596	non-dependent	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent
18-5	3597-3606	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
18-6	3607-3617	drug-using	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
18-7	3618-3626	controls	http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence
18-8	3627-3634	because	_
18-9	3635-3640	their	_
18-10	3641-3645	lack	_
18-11	3646-3648	of	_
18-12	3649-3659	dependence	_
18-13	3660-3667	reduced	_
18-14	3668-3673	their	_
18-15	3674-3684	likelihood	_
18-16	3685-3687	of	_
18-17	3688-3698	possessing	_
18-18	3699-3704	those	_
18-19	3705-3713	familial	_
18-20	3714-3718	risk	_
18-21	3719-3726	factors	_
18-22	3727-3730	and	_
18-23	3731-3741	associated	_
18-24	3742-3748	neural	_
18-25	3749-3764	vulnerabilities	_
18-26	3765-3769	that	_
18-27	3770-3776	render	_
18-28	3777-3788	individuals	_
18-29	3789-3800	susceptible	_
18-30	3801-3803	to	_
18-31	3804-3813	addiction	_
18-32	3814-3815	.	_

19-1	3816-3819	The	_
19-2	3820-3826	sample	_
19-3	3827-3831	size	_
19-4	3832-3835	was	_
19-5	3836-3846	determined	_
19-6	3847-3849	by	_
19-7	3850-3855	power	_
19-8	3856-3864	analysis	_
19-9	3865-3866	,	_
19-10	3867-3879	establishing	_
19-11	3880-3881	a	_
19-12	3882-3887	group	_
19-13	3888-3892	size	_
19-14	3893-3895	of	_
19-15	3896-3897	N	_
19-16	3898-3899	=	_
19-17	3900-3902	42	_
19-18	3903-3906	for	_
19-19	3907-3909	95	_
19-20	3910-3911	%	_
19-21	3912-3917	power	_
19-22	3918-3920	to	_
19-23	3921-3929	identify	_
19-24	3930-3933	the	_
19-25	3934-3941	effects	_
19-26	3942-3944	of	_
19-27	3945-3956	familiarity	_
19-28	3957-3958	.	_

20-1	3959-3974	Semi-structured	_
20-2	3975-3985	interviews	_
20-3	3986-3996	determined	_
20-4	3997-4001	that	_
20-5	4002-4009	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-6	4010-4022	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
20-7	4023-4026	had	_
20-8	4027-4029	no	_
20-9	4030-4042	first-degree	_
20-10	4043-4051	relative	_
20-11	4052-4060	affected	_
20-12	4061-4063	by	_
20-13	4064-4073	addiction	_
20-14	4074-4075	.	_

21-1	4076-4079	For	_
21-2	4080-4083	all	_
21-3	4084-4090	groups	_
21-4	4091-4092	,	_
21-5	4093-4105	exclusionary	_
21-6	4106-4114	criteria	_
21-7	4115-4123	included	_
21-8	4124-4125	a	_
21-9	4126-4134	lifetime	_
21-10	4135-4142	history	_
21-11	4143-4145	of	_
21-12	4146-4147	a	_
21-13	4148-4157	psychotic	_
21-14	4158-4159	,	_
21-15	4160-4172	neurological	_
21-16	4173-4174	,	_
21-17	4175-4177	or	_
21-18	4178-4194	neurodevelopment	_
21-19	4195-4203	disorder	_
21-20	4204-4205	,	_
21-21	4206-4208	or	_
21-22	4209-4218	traumatic	_
21-23	4219-4223	head	_
21-24	4224-4230	injury	_
21-25	4231-4232	.	_

22-1	4233-4242	Exclusion	_
22-2	4243-4251	criteria	_
22-3	4252-4255	for	_
22-4	4256-4266	unaffected	_
22-5	4267-4275	siblings	_
22-6	4276-4279	and	_
22-7	4280-4289	unrelated	_
22-8	4290-4298	controls	_
22-9	4299-4303	also	_
22-10	4304-4312	included	_
22-11	4313-4316	any	_
22-12	4317-4325	personal	_
22-13	4326-4333	history	_
22-14	4334-4336	of	_
22-15	4337-4346	substance	_
22-16	4347-4356	addiction	_
22-17	4357-4358	(	_
22-18	4359-4365	except	_
22-19	4366-4374	nicotine	_
22-20	4375-4376	)	_
22-21	4377-4378	.	_

23-1	4379-4389	Concurrent	_
23-2	4390-4394	drug	_
23-3	4395-4398	and	_
23-4	4399-4406	alcohol	_
23-5	4407-4418	consumption	_
23-6	4419-4422	for	_
23-7	4423-4428	these	_
23-8	4429-4434	three	_
23-9	4435-4441	groups	_
23-10	4442-4446	were	_
23-11	4447-4450	low	_
23-12	4451-4452	(	_
23-13	4453-4455	as	_
23-14	4456-4465	reflected	_
23-15	4466-4468	by	_
23-16	4469-4472	the	_
23-17	4473-4480	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-18	4481-4484	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-19	4485-4494	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-20	4495-4509	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-21	4510-4514	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-22	4515-4516	[	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-23	4517-4522	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-24	4523-4524	]	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-25	4525-4528	and	_
23-26	4529-4533	Drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse
23-27	4534-4539	Abuse	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse
23-28	4540-4549	Screening	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse
23-29	4550-4554	Test	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse
23-30	4555-4556	[	_
23-31	4557-4564	DAST-20	_
23-32	4565-4566	]	_
23-33	4567-4573	scores	_
23-34	4574-4575	,	_
23-35	4576-4579	see	_
23-36	4580-4585	Table	_
23-37	4586-4587	1	_
23-38	4588-4589	)	_
23-39	4590-4591	.	_

24-1	4592-4602	Experience	_
24-2	4603-4607	with	_
24-3	4608-4615	tobacco	_
24-4	4616-4619	and	_
24-5	4620-4628	nicotine	_
24-6	4629-4633	have	_
24-7	4634-4638	been	_
24-8	4639-4647	reported	_
24-9	4648-4650	in	_
24-10	4651-4654	all	_
24-11	4655-4661	groups	_
24-12	4662-4663	(	_
24-13	4664-4667	see	_
24-14	4668-4673	Table	_
24-15	4674-4675	1	_
24-16	4676-4677	)	_
24-17	4678-4679	.	_

25-1	4680-4685	Group	_
25-2	4686-4697	differences	_
25-3	4698-4700	in	_
25-4	4701-4709	reported	_
25-5	4710-4718	nicotine	_
25-6	4719-4720	(	_
25-7	4721-4723	Ï‡2	_
25-8	4724-4725	=	_
25-9	4726-4731	67.04	_
25-10	4732-4733	,	_
25-11	4734-4735	p	_
25-12	4736-4737	<	_
25-13	4738-4743	0.001	_
25-14	4744-4745	)	_
25-15	4746-4749	and	_
25-16	4750-4758	cannabis	_
25-17	4759-4762	use	_
25-18	4763-4764	(	_
25-19	4765-4767	Ï‡2	_
25-20	4768-4769	=	_
25-21	4770-4776	104.36	_
25-22	4777-4778	,	_
25-23	4779-4780	p	_
25-24	4781-4782	<	_
25-25	4783-4788	0.001	_
25-26	4789-4790	)	_
25-27	4791-4798	between	_
25-28	4799-4808	stimulant	_
25-29	4809-4813	drug	_
25-30	4814-4819	users	_
25-31	4820-4823	and	_
25-32	4824-4833	non-users	_
25-33	4834-4838	were	_
25-34	4839-4849	controlled	_
25-35	4850-4853	for	_
25-36	4854-4856	in	_
25-37	4857-4858	a	_
25-38	4859-4867	separate	_
25-39	4868-4876	post-hoc	_
25-40	4877-4885	analysis	_
25-41	4886-4887	.	_

26-1	4888-4898	Critically	_
26-2	4899-4900	,	_
26-3	4901-4909	although	_
26-4	4910-4921	drug-taking	_
26-5	4922-4933	experiences	_
26-6	4934-4937	are	_
26-7	4938-4944	common	_
26-8	4945-4947	in	_
26-9	4948-4954	people	_
26-10	4955-4959	with	_
26-11	4960-4968	familial	_
26-12	4969-4973	risk	_
26-13	4974-4975	,	_
26-14	4976-4980	F+Sâˆ’	_
26-15	4981-4993	participants	_
26-16	4994-4996	in	_
26-17	4997-5000	the	_
26-18	5001-5008	present	_
26-19	5009-5014	study	_
26-20	5015-5018	did	_
26-21	5019-5022	not	_
26-22	5023-5029	report	_
26-23	5030-5039	stimulant	_
26-24	5040-5044	drug	_
26-25	5045-5048	use	_
26-26	5049-5050	.	_

27-1	5051-5060	Exclusion	_
27-2	5061-5069	criteria	_
27-3	5070-5074	were	_
27-4	5075-5079	kept	_
27-5	5080-5092	deliberately	_
27-6	5093-5100	minimal	_
27-7	5101-5103	as	_
27-8	5104-5109	minor	_
27-9	5110-5125	psychopathology	_
27-10	5126-5129	may	_
27-11	5130-5132	be	_
27-12	5133-5134	a	_
27-13	5135-5143	clinical	_
27-14	5144-5150	marker	_
27-15	5151-5153	of	_
27-16	5154-5167	vulnerability	_
27-17	5168-5171	and	_
27-18	5172-5174	an	_
27-19	5175-5184	important	_
27-20	5185-5199	characteristic	_
27-21	5200-5202	of	_
27-22	5203-5206	the	_
27-23	5207-5218	participant	_
27-24	5219-5221	in	_
27-25	5222-5225	the	_
27-26	5226-5234	familial	_
27-27	5235-5239	risk	_
27-28	5240-5245	group	_
27-29	5246-5247	.	_

28-1	5248-5255	Further	_
28-2	5256-5263	details	_
28-3	5264-5267	can	_
28-4	5268-5270	be	_
28-5	5271-5276	found	_
28-6	5277-5279	in	_
28-7	5280-5283	the	_
28-8	5284-5297	supplementary	_
28-9	5298-5306	material	_
28-10	5307-5308	(	_
28-11	5309-5311	SM	_
28-12	5312-5313	)	_
28-13	5314-5315	.	_

29-1	5316-5318	In	_
29-2	5319-5327	addition	_
29-3	5328-5330	to	_
29-4	5331-5340	stimulant	_
29-5	5341-5345	drug	_
29-6	5346-5356	dependence	_
29-7	5357-5358	,	_
29-8	5359-5361	12	_
29-9	5362-5366	F+S+	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-10	5367-5379	participants	_
29-11	5380-5387	further	_
29-12	5388-5391	met	_
29-13	5392-5402	diagnostic	_
29-14	5403-5411	criteria	_
29-15	5412-5415	for	_
29-16	5416-5423	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
29-17	5424-5434	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
29-18	5435-5436	,	_
29-19	5437-5440	and	_
29-20	5441-5443	22	_
29-21	5444-5448	F+S+	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-22	5449-5461	participants	_
29-23	5462-5465	for	_
29-24	5466-5472	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
29-25	5473-5483	dependence	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
29-26	5484-5485	.	_

30-1	5486-5496	Consistent	_
30-2	5497-5501	with	_
30-3	5502-5507	prior	_
30-4	5508-5518	literature	_
30-5	5519-5520	,	_
30-6	5521-5533	participants	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
30-7	5534-5538	with	_
30-8	5539-5547	familial	_
30-9	5548-5552	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
30-10	5553-5561	reported	_
30-11	5562-5563	a	_
30-12	5564-5568	high	_
30-13	5569-5579	prevalence	_
30-14	5580-5582	of	_
30-15	5583-5592	childhood	_
30-16	5593-5602	adversity	_
30-17	5603-5607	when	_
30-18	5608-5616	compared	_
30-19	5617-5621	with	_
30-20	5622-5629	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
30-21	5630-5642	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
30-22	5643-5644	(	_
30-23	5645-5651	F1,159	_
30-24	5652-5653	=	_
30-25	5654-5659	29.12	_
30-26	5660-5661	,	_
30-27	5662-5663	p	_
30-28	5664-5665	<	_
30-29	5666-5671	0.001	_
30-30	5672-5673	)	_
30-31	5674-5675	,	_
30-32	5676-5678	as	_
30-33	5679-5689	determined	_
30-34	5690-5692	by	_
30-35	5693-5702	Childhood	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire
30-36	5703-5709	Trauma	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire
30-37	5710-5723	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire
30-38	5724-5725	(	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire
30-39	5726-5729	CTQ	http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire
30-40	5730-5731	)	_
30-41	5732-5737	abuse	_
30-42	5738-5744	scores	_
30-43	5745-5746	.	_

31-1	5747-5758	Differences	_
31-2	5759-5761	in	_
31-3	5762-5770	familial	_
31-4	5771-5783	relationship	_
31-5	5784-5791	between	_
31-6	5792-5799	sibling	_
31-7	5800-5805	pairs	_
31-8	5806-5809	and	_
31-9	5810-5819	unrelated	_
31-10	5820-5827	control	_
31-11	5828-5834	groups	_
31-12	5835-5836	(	_
31-13	5837-5841	i.e.	_
31-14	5842-5843	,	_
31-15	5844-5851	sibling	_
31-16	5852-5857	pairs	_
31-17	5858-5862	with	_
31-18	5863-5871	familial	_
31-19	5872-5876	risk	_
31-20	5877-5881	were	_
31-21	5882-5889	related	_
31-22	5890-5891	,	_
31-23	5892-5899	whereas	_
31-24	5900-5907	control	_
31-25	5908-5920	participants	_
31-26	5921-5928	without	_
31-27	5929-5937	familial	_
31-28	5938-5942	risk	_
31-29	5943-5947	were	_
31-30	5948-5951	not	_
31-31	5952-5953	)	_
31-32	5954-5957	was	_
31-33	5958-5970	investigated	_
31-34	5971-5979	post-hoc	_
31-35	5980-5981	.	_

32-1	5982-5987	Prior	_
32-2	5988-5990	to	_
32-3	5991-5998	testing	_
32-4	5999-6000	,	_
32-5	6001-6019	stimulant-positive	_
32-6	6020-6025	urine	_
32-7	6026-6033	samples	_
32-8	6034-6038	were	_
32-9	6039-6047	provided	_
32-10	6048-6050	by	_
32-11	6051-6054	all	_
32-12	6055-6061	except	_
32-13	6062-6067	three	_
32-14	6068-6072	F+S+	_
32-15	6073-6085	participants	_
32-16	6086-6087	,	_
32-17	6088-6098	indicating	_
32-18	6099-6102	the	_
32-19	6103-6106	use	_
32-20	6107-6109	of	_
32-21	6110-6119	stimulant	_
32-22	6120-6125	drugs	_
32-23	6126-6128	in	_
32-24	6129-6132	the	_
32-25	6133-6137	last	_
32-26	6138-6140	72	_
32-27	6141-6143	h.	_
32-28	6144-6157	Drug-negative	_
32-29	6158-6163	urine	_
32-30	6164-6171	samples	_
32-31	6172-6176	were	_
32-32	6177-6185	provided	_
32-33	6186-6188	by	_
32-34	6189-6192	all	_
32-35	6193-6198	other	_
32-36	6199-6211	participants	_
32-37	6212-6213	.	_

33-1	6214-6218	This	_
33-2	6219-6224	study	_
33-3	6225-6228	was	_
33-4	6229-6237	approved	_
33-5	6238-6240	by	_
33-6	6241-6244	the	_
33-7	6245-6248	NHS	_
33-8	6249-6264	Cambridgeshire2	_
33-9	6265-6273	Research	_
33-10	6274-6280	Ethics	_
33-11	6281-6290	Committee	_
33-12	6291-6292	(	_
33-13	6293-6307	08/H0308/310PI	_
33-14	6308-6309	:	_
33-15	6310-6313	KDE	_
33-16	6314-6315	)	_
33-17	6316-6317	,	_
33-18	6318-6321	and	_
33-19	6322-6329	written	_
33-20	6330-6338	informed	_
33-21	6339-6346	consent	_
33-22	6347-6350	was	_
33-23	6351-6359	obtained	_
33-24	6360-6364	from	_
33-25	6365-6368	all	_
33-26	6369-6381	participants	_
33-27	6382-6387	prior	_
33-28	6388-6390	to	_
33-29	6391-6396	study	_
33-30	6397-6407	enrollment	_
33-31	6408-6409	.	_

34-1	6410-6414	This	_
34-2	6415-6421	sample	_
34-3	6422-6424	is	_
34-4	6425-6434	described	_
34-5	6435-6437	in	_
34-6	6438-6442	more	_
34-7	6443-6449	detail	_
34-8	6450-6452	in	_
34-9	6453-6456	the	_
34-10	6457-6459	SM	_
34-11	6460-6461	;	_
34-12	6462-6470	separate	_
34-13	6471-6475	data	_
34-14	6476-6480	from	_
34-15	6481-6485	this	_
34-16	6486-6492	sample	_
34-17	6493-6497	have	_
34-18	6498-6502	been	_
34-19	6503-6512	published	_
34-20	6513-6523	previously	_
34-21	6524-6525	.	_

35-1	6526-6534	MID-task	_
35-2	6535-6541	design	_
35-3	6542-6544	We	_
35-4	6545-6549	used	_
35-5	6550-6553	the	_
35-6	6554-6562	MID-task	_
35-7	6563-6565	to	_
35-8	6566-6573	examine	_
35-9	6574-6577	the	_
35-10	6578-6584	neural	_
35-11	6585-6595	correlates	_
35-12	6596-6598	of	_
35-13	6599-6605	reward	_
35-14	6606-6618	anticipation	_
35-15	6619-6620	(	_
35-16	6621-6624	Fig	_
35-17	6625-6626	.	_

36-1	6627-6628	1	_
36-2	6629-6630	)	_
36-3	6631-6632	.	_

37-1	6633-6636	The	_
37-2	6637-6641	task	_
37-3	6642-6651	consisted	_
37-4	6652-6654	of	_
37-5	6655-6660	three	_
37-6	6661-6667	phases	_
37-7	6668-6669	:	_
37-8	6670-6682	anticipation	_
37-9	6683-6684	,	_
37-10	6685-6691	target	_
37-11	6692-6693	,	_
37-12	6694-6697	and	_
37-13	6698-6706	feedback	_
37-14	6707-6708	.	_

38-1	6709-6710	A	_
38-2	6711-6714	cue	_
38-3	6715-6724	presented	_
38-4	6725-6727	in	_
38-5	6728-6731	the	_
38-6	6732-6744	anticipation	_
38-7	6745-6750	phase	_
38-8	6751-6759	notified	_
38-9	6760-6772	participants	_
38-10	6773-6775	of	_
38-11	6776-6779	the	_
38-12	6780-6789	potential	_
38-13	6790-6792	to	_
38-14	6793-6800	receive	_
38-15	6801-6802	a	_
38-16	6803-6811	monetary	_
38-17	6812-6814	or	_
38-18	6815-6822	neutral	_
38-19	6823-6829	reward	_
38-20	6830-6831	.	_

39-1	6832-6835	The	_
39-2	6836-6842	target	_
39-3	6843-6851	stimulus	_
39-4	6852-6853	,	_
39-5	6854-6863	presented	_
39-6	6864-6873	following	_
39-7	6874-6877	the	_
39-8	6878-6890	anticipation	_
39-9	6891-6896	phase	_
39-10	6897-6898	,	_
39-11	6899-6907	prompted	_
39-12	6908-6920	participants	_
39-13	6921-6923	to	_
39-14	6924-6931	respond	_
39-15	6932-6934	by	_
39-16	6935-6943	pressing	_
39-17	6944-6945	a	_
39-18	6946-6952	button	_
39-19	6953-6954	.	_

40-1	6955-6962	Finally	_
40-2	6963-6964	,	_
40-3	6965-6971	during	_
40-4	6972-6975	the	_
40-5	6976-6984	feedback	_
40-6	6985-6990	phase	_
40-7	6991-7003	participants	_
40-8	7004-7008	were	_
40-9	7009-7017	informed	_
40-10	7018-7023	about	_
40-11	7024-7027	the	_
40-12	7028-7035	outcome	_
40-13	7036-7038	of	_
40-14	7039-7044	their	_
40-15	7045-7055	behavioral	_
40-16	7056-7064	response	_
40-17	7065-7066	.	_

41-1	7067-7073	During	_
41-2	7074-7077	the	_
41-3	7078-7090	anticipatory	_
41-4	7091-7096	phase	_
41-5	7097-7098	,	_
41-6	7099-7104	three	_
41-7	7105-7109	cues	_
41-8	7110-7111	,	_
41-9	7112-7122	indicating	_
41-10	7123-7129	either	_
41-11	7130-7131	a	_
41-12	7132-7139	neutral	_
41-13	7140-7142	or	_
41-14	7143-7152	rewarding	_
41-15	7153-7160	outcome	_
41-16	7161-7162	,	_
41-17	7163-7167	were	_
41-18	7168-7176	randomly	_
41-19	7177-7186	displayed	_
41-20	7187-7188	(	_
41-21	7189-7192	Fig	_
41-22	7193-7194	.	_

42-1	7195-7196	1	_
42-2	7197-7198	)	_
42-3	7199-7200	.	_

43-1	7201-7204	The	_
43-2	7205-7217	anticipatory	_
43-3	7218-7221	cue	_
43-4	7222-7225	was	_
43-5	7226-7235	presented	_
43-6	7236-7239	for	_
43-7	7240-7243	250	_
43-8	7244-7246	ms	_
43-9	7247-7248	,	_
43-10	7249-7257	notified	_
43-11	7258-7270	participants	_
43-12	7271-7273	of	_
43-13	7274-7277	the	_
43-14	7278-7287	potential	_
43-15	7288-7290	to	_
43-16	7291-7294	win	_
43-17	7295-7296	a	_
43-18	7297-7305	monetary	_
43-19	7306-7308	or	_
43-20	7309-7310	a	_
43-21	7311-7318	neutral	_
43-22	7319-7325	reward	_
43-23	7326-7327	,	_
43-24	7328-7331	and	_
43-25	7332-7335	was	_
43-26	7336-7344	followed	_
43-27	7345-7347	by	_
43-28	7348-7349	a	_
43-29	7350-7358	jittered	_
43-30	7359-7364	black	_
43-31	7365-7377	anticipation	_
43-32	7378-7384	screen	_
43-33	7385-7388	for	_
43-34	7389-7398	3000â€“5000	_
43-35	7399-7401	ms	_
43-36	7402-7403	.	_

44-1	7404-7407	The	_
44-2	7408-7414	target	_
44-3	7415-7423	stimulus	_
44-4	7424-7425	,	_
44-5	7426-7432	always	_
44-6	7433-7434	a	_
44-7	7435-7440	white	_
44-8	7441-7447	square	_
44-9	7448-7449	,	_
44-10	7450-7453	was	_
44-11	7454-7458	then	_
44-12	7459-7468	presented	_
44-13	7469-7472	for	_
44-14	7473-7480	100â€“400	_
44-15	7481-7483	ms	_
44-16	7484-7485	,	_
44-17	7486-7492	during	_
44-18	7493-7498	which	_
44-19	7499-7502	the	_
44-20	7503-7514	participant	_
44-21	7515-7518	had	_
44-22	7519-7521	to	_
44-23	7522-7529	respond	_
44-24	7530-7532	by	_
44-25	7533-7541	pressing	_
44-26	7542-7543	a	_
44-27	7544-7550	button	_
44-28	7551-7552	.	_

45-1	7553-7564	Immediately	_
45-2	7565-7574	following	_
45-3	7575-7578	the	_
45-4	7579-7585	target	_
45-5	7586-7594	stimulus	_
45-6	7595-7596	,	_
45-7	7597-7603	either	_
45-8	7604-7614	successful	_
45-9	7615-7617	or	_
45-10	7618-7630	unsuccessful	_
45-11	7631-7639	feedback	_
45-12	7640-7641	,	_
45-13	7642-7652	contingent	_
45-14	7653-7655	on	_
45-15	7656-7667	participant	_
45-16	7668-7676	response	_
45-17	7677-7678	,	_
45-18	7679-7682	was	_
45-19	7683-7692	presented	_
45-20	7693-7696	for	_
45-21	7697-7701	1650	_
45-22	7702-7704	ms	_
45-23	7705-7706	.	_

46-1	7707-7715	Feedback	_
46-2	7716-7723	screens	_
46-3	7724-7728	were	_
46-4	7729-7737	followed	_
46-5	7738-7740	by	_
46-6	7741-7742	a	_
46-7	7743-7751	fixation	_
46-8	7752-7757	cross	_
46-9	7758-7764	screen	_
46-10	7765-7766	,	_
46-11	7767-7772	which	_
46-12	7773-7776	was	_
46-13	7777-7786	presented	_
46-14	7787-7790	for	_
46-15	7791-7800	5000â€“2700	_
46-16	7801-7803	ms	_
46-17	7804-7809	until	_
46-18	7810-7813	the	_
46-19	7814-7818	next	_
46-20	7819-7824	trial	_
46-21	7825-7834	commenced	_
46-22	7835-7836	.	_

47-1	7837-7846	Responses	_
47-2	7847-7851	were	_
47-3	7852-7858	deemed	_
47-4	7859-7869	successful	_
47-5	7870-7872	if	_
47-6	7873-7882	performed	_
47-7	7883-7889	during	_
47-8	7890-7902	presentation	_
47-9	7903-7905	of	_
47-10	7906-7909	the	_
47-11	7910-7916	target	_
47-12	7917-7919	on	_
47-13	7920-7923	the	_
47-14	7924-7930	screen	_
47-15	7931-7932	.	_

48-1	7933-7936	The	_
48-2	7937-7941	time	_
48-3	7942-7949	between	_
48-4	7950-7953	the	_
48-5	7954-7966	presentation	_
48-6	7967-7969	of	_
48-7	7970-7973	the	_
48-8	7974-7977	cue	_
48-9	7978-7981	and	_
48-10	7982-7985	the	_
48-11	7986-7992	target	_
48-12	7993-8001	stimulus	_
48-13	8002-8012	represents	_
48-14	8013-8016	the	_
48-15	8017-8029	anticipatory	_
48-16	8030-8035	phase	_
48-17	8036-8037	,	_
48-18	8038-8044	during	_
48-19	8045-8050	which	_
48-20	8051-8057	neural	_
48-21	8058-8067	responses	_
48-22	8068-8072	were	_
48-23	8073-8081	recorded	_
48-24	8082-8083	(	_
48-25	8084-8087	Fig	_
48-26	8088-8089	.	_

49-1	8090-8091	1	_
49-2	8092-8093	)	_
49-3	8094-8095	.	_

50-1	8096-8101	Prior	_
50-2	8102-8104	to	_
50-3	8105-8113	scanning	_
50-4	8114-8115	,	_
50-5	8116-8119	all	_
50-6	8120-8132	participants	_
50-7	8133-8142	underwent	_
50-8	8143-8145	66	_
50-9	8146-8154	training	_
50-10	8155-8161	trials	_
50-11	8162-8164	to	_
50-12	8165-8171	ensure	_
50-13	8172-8176	they	_
50-14	8177-8180	had	_
50-15	8181-8182	a	_
50-16	8183-8188	clear	_
50-17	8189-8202	understanding	_
50-18	8203-8205	of	_
50-19	8206-8209	how	_
50-20	8210-8212	to	_
50-21	8213-8221	complete	_
50-22	8222-8225	the	_
50-23	8226-8230	task	_
50-24	8231-8232	.	_

51-1	8233-8245	Participants	_
51-2	8246-8250	were	_
51-3	8251-8255	told	_
51-4	8256-8261	prior	_
51-5	8262-8264	to	_
51-6	8265-8273	scanning	_
51-7	8274-8278	that	_
51-8	8279-8284	their	_
51-9	8285-8290	total	_
51-10	8291-8299	earnings	_
51-11	8300-8304	were	_
51-12	8305-8315	contingent	_
51-13	8316-8320	upon	_
51-14	8321-8325	task	_
51-15	8326-8337	performance	_
51-16	8338-8339	.	_

52-1	8340-8343	The	_
52-2	8344-8352	duration	_
52-3	8353-8355	of	_
52-4	8356-8359	the	_
52-5	8360-8372	anticipation	_
52-6	8373-8378	phase	_
52-7	8379-8382	was	_
52-8	8383-8388	based	_
52-9	8389-8391	on	_
52-10	8392-8404	participants	_
52-11	8405-8406	â€™	_
52-12	8407-8418	performance	_
52-13	8419-8421	to	_
52-14	8422-8430	maintain	_
52-15	8431-8432	a	_
52-16	8433-8435	66	_
52-17	8436-8437	%	_
52-18	8438-8445	success	_
52-19	8446-8450	rate	_
52-20	8451-8452	.	_

53-1	8453-8455	In	_
53-2	8456-8461	total	_
53-3	8462-8463	,	_
53-4	8464-8466	66	_
53-5	8467-8473	trials	_
53-6	8474-8478	were	_
53-7	8479-8488	completed	_
53-8	8489-8491	by	_
53-9	8492-8496	each	_
53-10	8497-8508	participant	_
53-11	8509-8510	.	_

54-1	8511-8523	Participants	_
54-2	8524-8528	also	_
54-3	8529-8538	completed	_
54-4	8539-8541	an	_
54-5	8542-8552	additional	_
54-6	8553-8554	,	_
54-7	8555-8558	but	_
54-8	8559-8567	separate	_
54-9	8568-8575	version	_
54-10	8576-8578	of	_
54-11	8579-8583	this	_
54-12	8584-8588	task	_
54-13	8589-8590	,	_
54-14	8591-8596	which	_
54-15	8597-8605	included	_
54-16	8606-8618	drug-related	_
54-17	8619-8623	cues	_
54-18	8624-8625	,	_
54-19	8626-8629	the	_
54-20	8630-8637	results	_
54-21	8638-8640	of	_
54-22	8641-8646	which	_
54-23	8647-8650	are	_
54-24	8651-8654	not	_
54-25	8655-8663	reported	_
54-26	8664-8668	here	_
54-27	8669-8670	.	_

55-1	8671-8682	Statistical	_
55-2	8683-8691	analysis	_
55-3	8692-8702	Behavioral	_
55-4	8703-8707	data	_
55-5	8708-8712	were	_
55-6	8713-8721	analyzed	_
55-7	8722-8727	using	_
55-8	8728-8731	the	_
55-9	8732-8743	Statistical	_
55-10	8744-8751	Package	_
55-11	8752-8755	for	_
55-12	8756-8762	Social	_
55-13	8763-8770	Science	_
55-14	8771-8772	(	_
55-15	8773-8777	SPSS	_
55-16	8778-8782	v.22	_
55-17	8783-8784	;	_
55-18	8785-8788	IBM	_
55-19	8789-8796	Chicago	_
55-20	8797-8798	,	_
55-21	8799-8807	Illinois	_
55-22	8808-8809	)	_
55-23	8810-8811	.	_

56-1	8812-8814	We	_
56-2	8815-8823	employed	_
56-3	8824-8825	a	_
56-4	8826-8836	univariate	_
56-5	8837-8845	analysis	_
56-6	8846-8848	of	_
56-7	8849-8857	variance	_
56-8	8858-8863	model	_
56-9	8864-8868	with	_
56-10	8869-8872	two	_
56-11	8873-8878	fixed	_
56-12	8879-8894	between-subject	_
56-13	8895-8902	factors	_
56-14	8903-8904	:	_
56-15	8905-8913	familial	_
56-16	8914-8918	risk	_
56-17	8919-8920	(	_
56-18	8921-8933	participants	_
56-19	8934-8938	with	_
56-20	8939-8942	and	_
56-21	8943-8950	without	_
56-22	8951-8960	addiction	_
56-23	8961-8963	in	_
56-24	8964-8967	the	_
56-25	8968-8974	family	_
56-26	8975-8976	)	_
56-27	8977-8980	and	_
56-28	8981-8991	stimulants	_
56-29	8992-8993	(	_
56-30	8994-9006	participants	_
56-31	9007-9011	with	_
56-32	9012-9015	and	_
56-33	9016-9023	without	_
56-34	9024-9033	stimulant	_
56-35	9034-9038	drug	_
56-36	9039-9042	use	_
56-37	9043-9044	)	_
56-38	9045-9046	.	_

57-1	9047-9051	This	_
57-2	9052-9063	statistical	_
57-3	9064-9069	model	_
57-4	9070-9077	allowed	_
57-5	9078-9081	the	_
57-6	9082-9090	separate	_
57-7	9091-9104	investigation	_
57-8	9105-9107	of	_
57-9	9108-9116	familial	_
57-10	9117-9121	risk	_
57-11	9122-9125	and	_
57-12	9126-9135	stimulant	_
57-13	9136-9140	drug	_
57-14	9141-9144	use	_
57-15	9145-9147	as	_
57-16	9148-9152	well	_
57-17	9153-9155	as	_
57-18	9156-9164	possible	_
57-19	9165-9177	interactions	_
57-20	9178-9185	between	_
57-21	9186-9191	these	_
57-22	9192-9195	two	_
57-23	9196-9203	factors	_
57-24	9204-9205	.	_

58-1	9206-9215	Analyzing	_
58-2	9216-9224	distinct	_
58-3	9225-9228	and	_
58-4	9229-9240	interacting	_
58-5	9241-9248	effects	_
58-6	9249-9255	within	_
58-7	9256-9259	the	_
58-8	9260-9264	same	_
58-9	9265-9270	model	_
58-10	9271-9274	not	_
58-11	9275-9279	only	_
58-12	9280-9289	mitigates	_
58-13	9290-9294	Type	_
58-14	9295-9296	I	_
58-15	9297-9302	error	_
58-16	9303-9306	but	_
58-17	9307-9310	can	_
58-18	9311-9315	also	_
58-19	9316-9322	reveal	_
58-20	9323-9335	interactions	_
58-21	9336-9343	between	_
58-22	9344-9349	these	_
58-23	9350-9353	two	_
58-24	9354-9361	factors	_
58-25	9362-9363	.	_

59-1	9364-9368	This	_
59-2	9369-9371	is	_
59-3	9372-9384	particularly	_
59-4	9385-9394	important	_
59-5	9395-9397	as	_
59-6	9398-9401	the	_
59-7	9402-9413	development	_
59-8	9414-9416	of	_
59-9	9417-9426	addiction	_
59-10	9427-9429	is	_
59-11	9430-9436	likely	_
59-12	9437-9447	contingent	_
59-13	9448-9450	on	_
59-14	9451-9455	both	_
59-15	9456-9459	the	_
59-16	9460-9463	use	_
59-17	9464-9466	of	_
59-18	9467-9472	drugs	_
59-19	9473-9476	and	_
59-20	9477-9485	familial	_
59-21	9486-9498	risk-factors	_
59-22	9499-9500	.	_

60-1	9501-9507	Gender	_
60-2	9508-9511	and	_
60-3	9512-9519	monthly	_
60-4	9520-9530	disposable	_
60-5	9531-9537	income	_
60-6	9538-9542	were	_
60-7	9543-9551	included	_
60-8	9552-9554	as	_
60-9	9555-9565	covariates	_
60-10	9566-9568	in	_
60-11	9569-9572	all	_
60-12	9573-9581	analyses	_
60-13	9582-9585	due	_
60-14	9586-9588	to	_
60-15	9589-9594	their	_
60-16	9595-9603	reported	_
60-17	9604-9615	involvement	_
60-18	9616-9618	in	_
60-19	9619-9625	reward	_
60-20	9626-9636	processing	_
60-21	9637-9640	and	_
60-22	9641-9644	the	_
60-23	9645-9656	development	_
60-24	9657-9659	of	_
60-25	9660-9669	addiction	_
60-26	9670-9671	,	_
60-27	9672-9675	and	_
60-28	9676-9678	to	_
60-29	9679-9686	control	_
60-30	9687-9690	for	_
60-31	9691-9696	group	_
60-32	9697-9708	differences	_
60-33	9709-9710	(	_
60-34	9711-9717	gender	_
60-35	9718-9719	:	_
60-36	9720-9722	Ï‡2	_
60-37	9723-9724	=	_
60-38	9725-9729	7.01	_
60-39	9730-9731	,	_
60-40	9732-9733	p	_
60-41	9734-9735	=	_
60-42	9736-9741	0.008	_
60-43	9742-9743	,	_
60-44	9744-9750	income	_
60-45	9751-9752	:	_
60-46	9753-9759	F1,155	_
60-47	9760-9761	=	_
60-48	9762-9766	5.40	_
60-49	9767-9768	,	_
60-50	9769-9770	p	_
60-51	9771-9772	=	_
60-52	9773-9778	0.021	_
60-53	9779-9780	)	_
60-54	9781-9782	.	_

61-1	9783-9788	These	_
61-2	9789-9800	differences	_
61-3	9801-9805	were	_
61-4	9806-9812	driven	_
61-5	9813-9815	by	_
61-6	9816-9820	male	_
61-7	9821-9830	dominance	_
61-8	9831-9833	in	_
61-9	9834-9837	the	_
61-10	9838-9842	F+S+	_
61-11	9843-9848	group	_
61-12	9849-9852	and	_
61-13	9853-9857	less	_
61-14	9858-9865	monthly	_
61-15	9866-9876	disposable	_
61-16	9877-9883	income	_
61-17	9884-9886	in	_
61-18	9887-9899	participants	_
61-19	9900-9904	with	_
61-20	9905-9913	familial	_
61-21	9914-9918	risk	_
61-22	9919-9920	,	_
61-23	9921-9933	irrespective	_
61-24	9934-9936	of	_
61-25	9937-9941	drug	_
61-26	9942-9945	use	_
61-27	9946-9947	.	_

62-1	9948-9960	Participants	_
62-2	9961-9965	with	_
62-3	9966-9970	less	_
62-4	9971-9976	money	_
62-5	9977-9979	to	_
62-6	9980-9985	spend	_
62-7	9986-9998	demonstrated	_
62-8	9999-10008	decreased	_
62-9	10009-10017	response	_
62-10	10018-10023	times	_
62-11	10024-10025	(	_
62-12	10026-10027	r	_
62-13	10028-10029	=	_
62-14	10030-10035	âˆ’0.18	_
62-15	10036-10037	,	_
62-16	10038-10039	p	_
62-17	10040-10041	=	_
62-18	10042-10047	0.022	_
62-19	10048-10049	)	_
62-20	10050-10051	.	_

63-1	10052-10057	Given	_
63-2	10058-10062	that	_
63-3	10063-10066	age	_
63-4	10067-10070	did	_
63-5	10071-10074	not	_
63-6	10075-10081	differ	_
63-7	10082-10089	between	_
63-8	10090-10096	groups	_
63-9	10097-10098	(	_
63-10	10099-10105	F3,155	_
63-11	10106-10107	=	_
63-12	10108-10112	2.60	_
63-13	10113-10114	,	_
63-14	10115-10116	p	_
63-15	10117-10118	=	_
63-16	10119-10124	0.054	_
63-17	10125-10126	)	_
63-18	10127-10130	and	_
63-19	10131-10134	was	_
63-20	10135-10138	not	_
63-21	10139-10149	correlated	_
63-22	10150-10154	with	_
63-23	10155-10162	outcome	_
63-24	10163-10171	measures	_
63-25	10172-10173	,	_
63-26	10174-10176	it	_
63-27	10177-10180	was	_
63-28	10181-10184	not	_
63-29	10185-10189	used	_
63-30	10190-10192	as	_
63-31	10193-10194	a	_
63-32	10195-10204	covariate	_
63-33	10205-10206	.	_

64-1	10207-10209	We	_
64-2	10210-10220	controlled	_
64-3	10221-10222	,	_
64-4	10223-10231	post-hoc	_
64-5	10232-10233	,	_
64-6	10234-10237	for	_
64-7	10238-10241	the	_
64-8	10242-10253	potentially	_
64-9	10254-10265	confounding	_
64-10	10266-10277	differences	_
64-11	10278-10280	in	_
64-12	10281-10284	the	_
64-13	10285-10302	severity/duration	_
64-14	10303-10305	of	_
64-15	10306-10310	drug	_
64-16	10311-10314	use	_
64-17	10315-10322	between	_
64-18	10323-10326	the	_
64-19	10327-10330	two	_
64-20	10331-10340	stimulant	_
64-21	10341-10346	using	_
64-22	10347-10353	groups	_
64-23	10354-10355	,	_
64-24	10356-10359	and	_
64-25	10360-10363	the	_
64-26	10364-10373	different	_
64-27	10374-10387	relationships	_
64-28	10388-10395	between	_
64-29	10396-10408	participants	_
64-30	10409-10411	in	_
64-31	10412-10415	the	_
64-32	10416-10422	groups	_
64-33	10423-10427	with	_
64-34	10428-10431	and	_
64-35	10432-10439	without	_
64-36	10440-10448	familial	_
64-37	10449-10453	risk	_
64-38	10454-10455	.	_

65-1	10456-10467	Accordingly	_
65-2	10468-10469	,	_
65-3	10470-10472	we	_
65-4	10473-10482	subjected	_
65-5	10483-10486	the	_
65-6	10487-10498	significant	_
65-7	10499-10511	neuroimaging	_
65-8	10512-10519	results	_
65-9	10520-10522	to	_
65-10	10523-10524	a	_
65-11	10525-10532	one-way	_
65-12	10533-10539	ANCOVA	_
65-13	10540-10548	analysis	_
65-14	10549-10551	by	_
65-15	10552-10561	importing	_
65-16	10562-10566	mean	_
65-17	10567-10574	cluster	_
65-18	10575-10579	beta	_
65-19	10580-10586	values	_
65-20	10587-10588	(	_
65-21	10589-10593	i.e.	_
65-22	10594-10595	,	_
65-23	10596-10600	mean	_
65-24	10601-10611	activation	_
65-25	10612-10614	or	_
65-26	10615-10627	connectivity	_
65-27	10628-10634	values	_
65-28	10635-10636	)	_
65-29	10637-10641	into	_
65-30	10642-10646	SPSS	_
65-31	10647-10648	.	_

66-1	10649-10651	To	_
66-2	10652-10659	control	_
66-3	10660-10663	for	_
66-4	10664-10675	differences	_
66-5	10676-10678	in	_
66-6	10679-10690	drug-taking	_
66-7	10691-10702	experiences	_
66-8	10703-10704	,	_
66-9	10705-10707	we	_
66-10	10708-10715	entered	_
66-11	10716-10719	the	_
66-12	10720-10729	following	_
66-13	10730-10739	variables	_
66-14	10740-10742	as	_
66-15	10743-10753	covariates	_
66-16	10754-10755	:	_
66-17	10756-10764	severity	_
66-18	10765-10767	of	_
66-19	10768-10777	stimulant	_
66-20	10778-10781	use	_
66-21	10782-10783	(	_
66-22	10784-10789	OCDUS	_
66-23	10790-10795	score	_
66-24	10796-10797	)	_
66-25	10798-10799	,	_
66-26	10800-10805	years	_
66-27	10806-10808	of	_
66-28	10809-10818	stimulant	_
66-29	10819-10823	drug	_
66-30	10824-10827	use	_
66-31	10828-10829	,	_
66-32	10830-10837	alcohol	_
66-33	10838-10849	consumption	_
66-34	10850-10851	(	_
66-35	10852-10857	AUDIT	_
66-36	10858-10863	score	_
66-37	10864-10865	)	_
66-38	10866-10867	,	_
66-39	10868-10880	current/past	_
66-40	10881-10889	nicotine	_
66-41	10890-10893	use	_
66-42	10894-10895	,	_
66-43	10896-10899	and	_
66-44	10900-10912	current/past	_
66-45	10913-10921	cannabis	_
66-46	10922-10925	use	_
66-47	10926-10927	.	_

67-1	10928-10930	To	_
67-2	10931-10938	control	_
67-3	10939-10942	for	_
67-4	10943-10946	the	_
67-5	10947-10953	shared	_
67-6	10954-10965	environment	_
67-7	10966-10968	of	_
67-8	10969-10972	the	_
67-9	10973-10980	sibling	_
67-10	10981-10986	pairs	_
67-11	10987-10988	,	_
67-12	10989-10991	we	_
67-13	10992-10999	further	_
67-14	11000-11008	included	_
67-15	11009-11010	a	_
67-16	11011-11018	measure	_
67-17	11019-11021	of	_
67-18	11022-11031	childhood	_
67-19	11032-11041	adversity	_
67-20	11042-11043	(	_
67-21	11044-11047	CTQ	_
67-22	11048-11053	abuse	_
67-23	11054-11059	score	_
67-24	11060-11061	)	_
67-25	11062-11064	as	_
67-26	11065-11066	a	_
67-27	11067-11076	covariate	_
67-28	11077-11079	in	_
67-29	11080-11083	the	_
67-30	11084-11088	same	_
67-31	11089-11097	post-hoc	_
67-32	11098-11104	ANCOVA	_
67-33	11105-11110	model	_
67-34	11111-11112	.	_

68-1	11113-11115	We	_
68-2	11116-11119	did	_
68-3	11120-11123	not	_
68-4	11124-11131	include	_
68-5	11132-11137	these	_
68-6	11138-11147	variables	_
68-7	11148-11150	as	_
68-8	11151-11161	covariates	_
68-9	11162-11164	in	_
68-10	11165-11168	the	_
68-11	11169-11173	main	_
68-12	11174-11182	analysis	_
68-13	11183-11185	to	_
68-14	11186-11191	avoid	_
68-15	11192-11205	statistically	_
68-16	11206-11217	controlling	_
68-17	11218-11221	for	_
68-18	11222-11229	aspects	_
68-19	11230-11234	that	_
68-20	11235-11239	were	_
68-21	11240-11248	critical	_
68-22	11249-11251	in	_
68-23	11252-11260	defining	_
68-24	11261-11264	the	_
68-25	11265-11271	groups	_
68-26	11272-11273	.	_

69-1	11274-11284	Behavioral	_
69-2	11285-11289	data	_
69-3	11290-11294	were	_
69-4	11295-11303	analyzed	_
69-5	11304-11307	for	_
69-6	11308-11316	accuracy	_
69-7	11317-11320	and	_
69-8	11321-11328	latency	_
69-9	11329-11331	of	_
69-10	11332-11342	successful	_
69-11	11343-11349	trials	_
69-12	11350-11351	,	_
69-13	11352-11355	and	_
69-14	11356-11359	the	_
69-15	11360-11365	total	_
69-16	11366-11372	amount	_
69-17	11373-11375	of	_
69-18	11376-11381	money	_
69-19	11382-11388	gained	_
69-20	11389-11394	using	_
69-21	11395-11396	a	_
69-22	11397-11414	repeated-measures	_
69-23	11415-11421	ANCOVA	_
69-24	11422-11427	model	_
69-25	11428-11432	with	_
69-26	11433-11438	trial	_
69-27	11439-11443	type	_
69-28	11444-11445	(	_
69-29	11446-11454	monetary	_
69-30	11455-11461	versus	_
69-31	11462-11469	neutral	_
69-32	11470-11476	reward	_
69-33	11477-11478	)	_
69-34	11479-11481	as	_
69-35	11482-11485	the	_
69-36	11486-11500	within-subject	_
69-37	11501-11507	factor	_
69-38	11508-11511	and	_
69-39	11512-11522	stimulants	_
69-40	11523-11526	and	_
69-41	11527-11535	familial	_
69-42	11536-11540	risk	_
69-43	11541-11543	as	_
69-44	11544-11547	the	_
69-45	11548-11551	two	_
69-46	11552-11567	between-subject	_
69-47	11568-11575	factors	_
69-48	11576-11577	.	_

70-1	11578-11589	Square-root	_
70-2	11590-11604	transformation	_
70-3	11605-11608	was	_
70-4	11609-11613	used	_
70-5	11614-11617	for	_
70-6	11618-11622	best	_
70-7	11623-11636	normalization	_
70-8	11637-11638	.	_

71-1	11639-11644	Sidak	_
71-2	11645-11653	post-hoc	_
71-3	11654-11662	analysis	_
71-4	11663-11666	was	_
71-5	11667-11671	used	_
71-6	11672-11675	for	_
71-7	11676-11679	all	_
71-8	11680-11690	individual	_
71-9	11691-11696	group	_
71-10	11697-11708	comparisons	_
71-11	11709-11710	.	_

72-1	11711-11722	Accordingly	_
72-2	11723-11724	,	_
72-3	11725-11736	demographic	_
72-4	11737-11741	data	_
72-5	11742-11746	were	_
72-6	11747-11755	analyzed	_
72-7	11756-11761	using	_
72-8	11762-11763	a	_
72-9	11764-11771	general	_
72-10	11772-11778	linear	_
72-11	11779-11784	model	_
72-12	11785-11786	(	_
72-13	11787-11790	GLM	_
72-14	11791-11792	)	_
72-15	11793-11797	with	_
72-16	11798-11808	stimulants	_
72-17	11809-11812	and	_
72-18	11813-11821	familial	_
72-19	11822-11826	risk	_
72-20	11827-11829	as	_
72-21	11830-11835	fixed	_
72-22	11836-11843	factors	_
72-23	11844-11845	.	_

73-1	11846-11857	Demographic	_
73-2	11858-11861	and	_
73-3	11862-11866	task	_
73-4	11867-11878	performance	_
73-5	11879-11883	data	_
73-6	11884-11888	were	_
73-7	11889-11893	used	_
73-8	11894-11897	for	_
73-9	11898-11906	analyses	_
73-10	11907-11908	(	_
73-11	11909-11912	see	_
73-12	11913-11918	Table	_
73-13	11919-11920	1	_
73-14	11921-11922	)	_
73-15	11923-11924	.	_

74-1	11925-11932	Pearson	_
74-2	11933-11944	correlation	_
74-3	11945-11957	coefficients	_
74-4	11958-11962	were	_
74-5	11963-11973	calculated	_
74-6	11974-11976	to	_
74-7	11977-11983	assess	_
74-8	11984-11987	the	_
74-9	11988-12001	relationships	_
74-10	12002-12009	between	_
74-11	12010-12017	outcome	_
74-12	12018-12026	measures	_
74-13	12027-12028	.	_

75-1	12029-12031	We	_
75-2	12032-12036	also	_
75-3	12037-12045	examined	_
75-4	12046-12049	the	_
75-5	12050-12062	relationship	_
75-6	12063-12070	between	_
75-7	12071-12084	self-reported	_
75-8	12085-12096	impulsivity	_
75-9	12097-12100	and	_
75-10	12101-12113	task-related	_
75-11	12114-12120	neural	_
75-12	12121-12131	activation	_
75-13	12132-12135	and	_
75-14	12136-12146	functional	_
75-15	12147-12159	connectivity	_
75-16	12160-12165	using	_
75-17	12166-12169	the	_
75-18	12170-12177	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
75-19	12178-12191	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
75-20	12192-12197	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
75-21	12198-12199	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
75-22	12200-12206	BIS-11	_
75-23	12207-12208	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
75-24	12209-12210	.	_

76-1	12211-12214	All	_
76-2	12215-12220	tests	_
76-3	12221-12225	were	_
76-4	12226-12236	two-tailed	_
76-5	12237-12240	and	_
76-6	12241-12253	significance	_
76-7	12254-12260	levels	_
76-8	12261-12263	of	_
76-9	12264-12265	p	_
76-10	12266-12267	<	_
76-11	12268-12272	0.05	_
76-12	12273-12277	were	_
76-13	12278-12285	assumed	_
76-14	12286-12287	.	_

77-1	12288-12300	Neuroimaging	_
77-2	12301-12305	data	_
77-3	12306-12317	acquisition	_
77-4	12318-12321	and	_
77-5	12322-12330	analysis	_
77-6	12331-12338	Further	_
77-7	12339-12346	details	_
77-8	12347-12349	on	_
77-9	12350-12362	neuroimaging	_
77-10	12363-12367	data	_
77-11	12368-12379	acquisition	_
77-12	12380-12383	and	_
77-13	12384-12392	analysis	_
77-14	12393-12396	can	_
77-15	12397-12399	be	_
77-16	12400-12405	found	_
77-17	12406-12408	in	_
77-18	12409-12412	the	_
77-19	12413-12415	SM	_
77-20	12416-12417	.	_

78-1	12418-12425	Briefly	_
78-2	12426-12427	,	_
78-3	12428-12440	neuroimaging	_
78-4	12441-12445	data	_
78-5	12446-12450	were	_
78-6	12451-12459	acquired	_
78-7	12460-12462	at	_
78-8	12463-12466	the	_
78-9	12467-12474	Wolfson	_
78-10	12475-12480	Brain	_
78-11	12481-12488	Imaging	_
78-12	12489-12495	Centre	_
78-13	12496-12497	,	_
78-14	12498-12508	University	_
78-15	12509-12511	of	_
78-16	12512-12521	Cambridge	_
78-17	12522-12523	,	_
78-18	12524-12526	in	_
78-19	12527-12530	one	_
78-20	12531-12534	run	_
78-21	12535-12537	on	_
78-22	12538-12539	a	_
78-23	12540-12547	Siemens	_
78-24	12548-12556	TIM-Trio	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
78-25	12557-12564	3-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
78-26	12565-12572	scanner	http://maven.renci.org/NeuroBridge/neurobridge#DateTimeUnit
78-27	12573-12574	(	_
78-28	12575-12582	Siemens	_
78-29	12583-12590	Medical	_
78-30	12591-12600	Solutions	_
78-31	12601-12602	,	_
78-32	12603-12611	Erlangen	_
78-33	12612-12613	,	_
78-34	12614-12621	Germany	_
78-35	12622-12623	)	_
78-36	12624-12625	.	_

79-1	12626-12629	The	_
79-2	12630-12635	scans	_
79-3	12636-12640	were	_
79-4	12641-12649	analyzed	_
79-5	12650-12652	in	_
79-6	12653-12658	FMRIB	_
79-7	12659-12660	â€™	_
79-8	12661-12662	s	_
79-9	12663-12671	Software	_
79-10	12672-12679	Library	_
79-11	12680-12681	(	_
79-12	12682-12685	FSL	_
79-13	12686-12687	,	_
79-14	12688-12695	v-5.0.9	_
79-15	12696-12697	,	_
79-16	12698-12703	https	_
79-17	12704-12705	:	_
79-18	12706-12730	//fsl.fmrib.ox.ac.uk/fsl	_
79-19	12731-12732	)	_
79-20	12733-12736	and	_
79-21	12737-12746	consisted	_
79-22	12747-12749	of	_
79-23	12750-12753	two	_
79-24	12754-12758	main	_
79-25	12759-12765	stages	_
79-26	12766-12767	:	_
79-27	12768-12769	(	_
79-28	12770-12771	1	_
79-29	12772-12773	)	_
79-30	12774-12778	task	_
79-31	12779-12789	activation	_
79-32	12790-12798	analysis	_
79-33	12799-12801	to	_
79-34	12802-12810	identify	_
79-35	12811-12816	brain	_
79-36	12817-12824	regions	_
79-37	12825-12833	involved	_
79-38	12834-12836	in	_
79-39	12837-12843	reward	_
79-40	12844-12854	processing	_
79-41	12855-12858	and	_
79-42	12859-12866	effects	_
79-43	12867-12869	of	_
79-44	12870-12878	interest	_
79-45	12879-12880	(	_
79-46	12881-12885	i.e.	_
79-47	12886-12887	,	_
79-48	12888-12892	main	_
79-49	12893-12900	effects	_
79-50	12901-12903	of	_
79-51	12904-12912	familial	_
79-52	12913-12917	risk	_
79-53	12918-12919	,	_
79-54	12920-12929	stimulant	_
79-55	12930-12934	drug	_
79-56	12935-12938	use	_
79-57	12939-12940	,	_
79-58	12941-12944	and	_
79-59	12945-12950	their	_
79-60	12951-12962	interaction	_
79-61	12963-12964	)	_
79-62	12965-12966	;	_
79-63	12967-12968	(	_
79-64	12969-12970	2	_
79-65	12971-12972	)	_
79-66	12973-12981	post-hoc	_
79-67	12982-13001	psychophysiological	_
79-68	13002-13013	interaction	_
79-69	13014-13015	(	_
79-70	13016-13019	PPI	_
79-71	13020-13021	)	_
79-72	13022-13030	analysis	_
79-73	13031-13033	to	_
79-74	13034-13041	further	_
79-75	13042-13049	explore	_
79-76	13050-13060	functional	_
79-77	13061-13073	connectivity	_
79-78	13074-13081	related	_
79-79	13082-13084	to	_
79-80	13085-13091	reward	_
79-81	13092-13104	anticipation	_
79-82	13105-13108	and	_
79-83	13109-13116	effects	_
79-84	13117-13119	of	_
79-85	13120-13128	interest	_
79-86	13129-13130	.	_

80-1	13131-13140	Following	_
80-2	13141-13149	standard	_
80-3	13150-13164	pre-processing	_
80-4	13165-13175	procedures	_
80-5	13176-13177	,	_
80-6	13178-13189	statistical	_
80-7	13190-13198	analyses	_
80-8	13199-13203	were	_
80-9	13204-13213	conducted	_
80-10	13214-13216	at	_
80-11	13217-13220	the	_
80-12	13221-13226	first	_
80-13	13227-13230	and	_
80-14	13231-13237	second	_
80-15	13238-13244	levels	_
80-16	13245-13247	by	_
80-17	13248-13253	using	_
80-18	13254-13258	fMRI	_
80-19	13259-13265	Expert	_
80-20	13266-13274	Analysis	_
80-21	13275-13279	Tool	_
80-22	13280-13281	.	_

81-1	13282-13284	At	_
81-2	13285-13288	the	_
81-3	13289-13294	first	_
81-4	13295-13300	level	_
81-5	13301-13302	,	_
81-6	13303-13306	GLM	_
81-7	13307-13315	analysis	_
81-8	13316-13319	was	_
81-9	13320-13329	conducted	_
81-10	13330-13333	for	_
81-11	13334-13338	each	_
81-12	13339-13350	participant	_
81-13	13351-13352	.	_

82-1	13353-13355	As	_
82-2	13356-13362	reward	_
82-3	13363-13372	magnitude	_
82-4	13373-13379	showed	_
82-5	13380-13382	no	_
82-6	13383-13393	behavioral	_
82-7	13394-13405	differences	_
82-8	13406-13408	in	_
82-9	13409-13416	latency	_
82-10	13417-13418	,	_
82-11	13419-13427	accuracy	_
82-12	13428-13429	,	_
82-13	13430-13432	or	_
82-14	13433-13438	brain	_
82-15	13439-13449	activation	_
82-16	13450-13451	,	_
82-17	13452-13457	small	_
82-18	13458-13461	and	_
82-19	13462-13467	large	_
82-20	13468-13475	rewards	_
82-21	13476-13480	were	_
82-22	13481-13490	collapsed	_
82-23	13491-13500	resulting	_
82-24	13501-13503	in	_
82-25	13504-13505	a	_
82-26	13506-13512	single	_
82-27	13513-13521	monetary	_
82-28	13522-13528	reward	_
82-29	13529-13533	type	_
82-30	13534-13535	.	_

83-1	13536-13545	Contrasts	_
83-2	13546-13548	of	_
83-3	13549-13557	interest	_
83-4	13558-13566	included	_
83-5	13567-13568	:	_
83-6	13569-13581	anticipation	_
83-7	13582-13584	of	_
83-8	13585-13593	monetary	_
83-9	13594-13600	reward	_
83-10	13601-13607	versus	_
83-11	13608-13615	neutral	_
83-12	13616-13622	reward	_
83-13	13623-13624	,	_
83-14	13625-13635	successful	_
83-15	13636-13644	feedback	_
83-16	13645-13646	,	_
83-17	13647-13650	and	_
83-18	13651-13663	unsuccessful	_
83-19	13664-13672	feedback	_
83-20	13673-13674	(	_
83-21	13675-13682	results	_
83-22	13683-13685	on	_
83-23	13686-13694	feedback	_
83-24	13695-13698	are	_
83-25	13699-13707	reported	_
83-26	13708-13710	in	_
83-27	13711-13714	the	_
83-28	13715-13717	SM	_
83-29	13718-13719	)	_
83-30	13720-13721	,	_
83-31	13722-13732	consistent	_
83-32	13733-13737	with	_
83-33	13738-13743	prior	_
83-34	13744-13754	literature	_
83-35	13755-13756	.	_

84-1	13757-13759	At	_
84-2	13760-13763	the	_
84-3	13764-13770	second	_
84-4	13771-13776	level	_
84-5	13777-13778	,	_
84-6	13779-13782	the	_
84-7	13783-13787	main	_
84-8	13788-13794	effect	_
84-9	13795-13797	of	_
84-10	13798-13802	each	_
84-11	13803-13811	contrast	_
84-12	13812-13821	collapsed	_
84-13	13822-13828	across	_
84-14	13829-13835	groups	_
84-15	13836-13839	was	_
84-16	13840-13848	computed	_
84-17	13849-13854	using	_
84-18	13855-13865	one-sample	_
84-19	13866-13873	t-tests	_
84-20	13874-13875	,	_
84-21	13876-13880	with	_
84-22	13881-13887	gender	_
84-23	13888-13891	and	_
84-24	13892-13899	monthly	_
84-25	13900-13910	disposable	_
84-26	13911-13917	income	_
84-27	13918-13920	as	_
84-28	13921-13931	covariates	_
84-29	13932-13933	,	_
84-30	13934-13936	to	_
84-31	13937-13943	reveal	_
84-32	13944-13948	task	_
84-33	13949-13959	activation	_
84-34	13960-13968	patterns	_
84-35	13969-13970	.	_

85-1	13971-13974	The	_
85-2	13975-13981	ANCOVA	_
85-3	13982-13987	model	_
85-4	13988-13991	was	_
85-5	13992-13996	used	_
85-6	13997-13999	to	_
85-7	14000-14006	assess	_
85-8	14007-14011	main	_
85-9	14012-14019	effects	_
85-10	14020-14022	of	_
85-11	14023-14033	stimulants	_
85-12	14034-14037	and	_
85-13	14038-14046	familial	_
85-14	14047-14051	risk	_
85-15	14052-14054	in	_
85-16	14055-14058	the	_
85-17	14059-14063	four	_
85-18	14064-14070	groups	_
85-19	14071-14073	as	_
85-20	14074-14078	well	_
85-21	14079-14081	as	_
85-22	14082-14087	their	_
85-23	14088-14099	interaction	_
85-24	14100-14103	for	_
85-25	14104-14108	each	_
85-26	14109-14117	contrast	_
85-27	14118-14119	.	_

86-1	14120-14122	In	_
86-2	14123-14126	the	_
86-3	14127-14133	second	_
86-4	14134-14139	stage	_
86-5	14140-14141	,	_
86-6	14142-14147	owing	_
86-7	14148-14150	to	_
86-8	14151-14159	observed	_
86-9	14160-14172	task-related	_
86-10	14173-14183	activation	_
86-11	14184-14186	in	_
86-12	14187-14190	the	_
86-13	14191-14198	putamen	_
86-14	14199-14200	,	_
86-15	14201-14209	post-hoc	_
86-16	14210-14221	exploratory	_
86-17	14222-14225	PPI	_
86-18	14226-14234	analysis	_
86-19	14235-14238	was	_
86-20	14239-14243	used	_
86-21	14244-14251	between	_
86-22	14252-14260	striatal	_
86-23	14261-14265	seed	_
86-24	14266-14273	regions	_
86-25	14274-14276	of	_
86-26	14277-14286	interests	_
86-27	14287-14288	(	_
86-28	14289-14292	ROI	_
86-29	14293-14294	)	_
86-30	14295-14298	and	_
86-31	14299-14304	whole	_
86-32	14305-14310	brain	_
86-33	14311-14312	.	_

87-1	14313-14316	The	_
87-2	14317-14321	seed	_
87-3	14322-14325	ROI	_
87-4	14326-14329	was	_
87-5	14330-14337	defined	_
87-6	14338-14340	by	_
87-7	14341-14344	the	_
87-8	14345-14349	peak	_
87-9	14350-14361	coordinates	_
87-10	14362-14364	of	_
87-11	14365-14368	the	_
87-12	14369-14380	significant	_
87-13	14381-14388	putamen	_
87-14	14389-14396	cluster	_
87-15	14397-14406	extracted	_
87-16	14407-14411	from	_
87-17	14412-14413	a	_
87-18	14414-14419	group	_
87-19	14420-14425	level	_
87-20	14426-14430	with	_
87-21	14431-14432	a	_
87-22	14433-14434	4	_
87-23	14435-14437	mm	_
87-24	14438-14444	radius	_
87-25	14445-14446	.	_

88-1	14447-14450	For	_
88-2	14451-14454	all	_
88-3	14455-14463	analyses	_
88-4	14464-14465	,	_
88-5	14466-14477	significant	_
88-6	14478-14485	effects	_
88-7	14486-14490	were	_
88-8	14491-14498	defined	_
88-9	14499-14500	,	_
88-10	14501-14506	after	_
88-11	14507-14516	voxelwise	_
88-12	14517-14524	testing	_
88-13	14525-14528	and	_
88-14	14529-14540	family-wise	_
88-15	14541-14546	error	_
88-16	14547-14548	(	_
88-17	14549-14552	FWE	_
88-18	14553-14554	)	_
88-19	14555-14565	correction	_
88-20	14566-14569	for	_
88-21	14570-14578	multiple	_
88-22	14579-14589	comparison	_
88-23	14590-14591	,	_
88-24	14592-14594	as	_
88-25	14595-14603	clusters	_
88-26	14604-14608	with	_
88-27	14609-14610	a	_
88-28	14611-14616	voxel	_
88-29	14617-14623	height	_
88-30	14624-14626	of	_
88-31	14627-14628	Z	_
88-32	14629-14630	>	_
88-33	14631-14635	2.58	_
88-34	14636-14637	(	_
88-35	14638-14642	i.e.	_
88-36	14643-14644	,	_
88-37	14645-14646	p	_
88-38	14647-14648	<	_
88-39	14649-14654	0.005	_
88-40	14655-14656	)	_
88-41	14657-14660	and	_
88-42	14661-14678	cluster-corrected	_
88-43	14679-14686	p-value	_
88-44	14687-14689	of	_
88-45	14690-14697	0.00015	_
88-46	14698-14699	(	_
88-47	14700-14705	using	_
88-48	14706-14709	FSL	_
88-49	14710-14711	â€™	_
88-50	14712-14713	s	_
88-51	14714-14724	easythresh	_
88-52	14725-14733	function	_
88-53	14734-14735	)	_
88-54	14736-14737	.	_

89-1	14738-14741	Due	_
89-2	14742-14744	to	_
89-3	14745-14751	recent	_
89-4	14752-14763	discussions	_
89-5	14764-14773	regarding	_
89-6	14774-14777	the	_
89-7	14778-14785	control	_
89-8	14786-14788	of	_
89-9	14789-14794	false	_
89-10	14795-14804	positives	_
89-11	14805-14807	in	_
89-12	14808-14815	cluster	_
89-13	14816-14825	inference	_
89-14	14826-14827	,	_
89-15	14828-14830	we	_
89-16	14831-14839	employed	_
89-17	14840-14841	a	_
89-18	14842-14852	relatively	_
89-19	14853-14857	more	_
89-20	14858-14867	stringent	_
89-21	14868-14877	threshold	_
89-22	14878-14882	than	_
89-23	14883-14886	the	_
89-24	14887-14899	conventional	_
89-25	14900-14901	Z	_
89-26	14902-14903	>	_
89-27	14904-14907	2.3	_
89-28	14908-14909	(	_
89-29	14910-14914	i.e.	_
89-30	14915-14916	,	_
89-31	14917-14918	p	_
89-32	14919-14920	<	_
89-33	14921-14924	.01	_
89-34	14925-14926	)	_
89-35	14927-14928	.	_

90-1	14929-14931	Of	_
90-2	14932-14935	the	_
90-3	14936-14940	nine	_
90-4	14941-14953	participants	_
90-5	14954-14958	that	_
90-6	14959-14963	were	_
90-7	14964-14972	excluded	_
90-8	14973-14981	post-hoc	_
90-9	14982-14983	,	_
90-10	14984-14988	five	_
90-11	14989-14993	were	_
90-12	14994-14997	due	_
90-13	14998-15000	to	_
90-14	15001-15010	excessive	_
90-15	15011-15015	head	_
90-16	15016-15022	motion	_
90-17	15023-15029	during	_
90-18	15030-15038	scanning	_
90-19	15039-15040	(	_
90-20	15041-15042	1	_
90-21	15043-15047	Fâˆ’Sâˆ’	_
90-22	15048-15049	,	_
90-23	15050-15051	3	_
90-24	15052-15056	F+S+	_
90-25	15057-15058	,	_
90-26	15059-15060	1	_
90-27	15061-15065	F+Sâˆ’	_
90-28	15066-15067	)	_
90-29	15068-15069	,	_
90-30	15070-15073	one	_
90-31	15074-15077	due	_
90-32	15078-15080	to	_
90-33	15081-15085	poor	_
90-34	15086-15090	data	_
90-35	15091-15098	quality	_
90-36	15099-15100	(	_
90-37	15101-15102	1	_
90-38	15103-15107	F+Sâˆ’	_
90-39	15108-15109	)	_
90-40	15110-15111	,	_
90-41	15112-15115	and	_
90-42	15116-15121	three	_
90-43	15122-15125	due	_
90-44	15126-15128	to	_
90-45	15129-15139	incomplete	_
90-46	15140-15150	behavioral	_
90-47	15151-15155	data	_
90-48	15156-15157	(	_
90-49	15158-15159	1	_
90-50	15160-15163	F+S	_
90-51	15164-15165	+	_
90-52	15166-15167	,	_
90-53	15168-15169	1	_
90-54	15170-15174	F+Sâˆ’	_
90-55	15175-15176	,	_
90-56	15177-15178	1	_
90-57	15179-15183	Fâˆ’S+	_
90-58	15184-15185	)	_
90-59	15186-15187	,	_
90-60	15188-15197	resulting	_
90-61	15198-15200	in	_
90-62	15201-15202	a	_
90-63	15203-15212	remaining	_
90-64	15213-15219	sample	_
90-65	15220-15222	of	_
90-66	15223-15226	160	_
90-67	15227-15239	participants	_
90-68	15240-15241	.	_

91-1	15242-15250	Baseline	_
91-2	15251-15262	demographic	_
91-3	15263-15278	characteristics	_
91-4	15279-15282	did	_
91-5	15283-15286	not	_
91-6	15287-15293	differ	_
91-7	15294-15301	between	_
91-8	15302-15310	excluded	_
91-9	15311-15314	and	_
91-10	15315-15323	included	_
91-11	15324-15336	participants	_
91-12	15337-15338	.	_

